Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: biotech/medical – Page 10

Oxygen is essential for life and a reactive player in many chemical processes. Accordingly, methods that accurately measure oxygen are relevant for numerous industrial and medical applications: They analyze exhaust gases from combustion processes, enable the oxygen-free processing of food and medicines, monitor the oxygen content of the air we breathe or the oxygen saturation in blood.

Oxygen analysis is also playing an increasingly important role in .

“However, such measurements usually require bulky, power-hungry, and expensive devices that are hardly suitable for mobile applications or continuous outdoor use,” says Máté Bezdek, Professor of Functional Coordination Chemistry at ETH Zurich. His group uses molecular design methods to find new sensors for environmental gases.

Read more | >

Researchers at Michigan State University have refined an innovation that has the potential to improve safety, reduce severe injury and increase survival rates in situations ranging from car accidents, sports, law enforcement operations and more.

In 2020 and 2022, Weiyi Lu, an associate professor in MSU’s College of Engineering, developed a liquid nanofoam material made up of tiny holes surrounded by water that has been shown to protect the brain against traumatic injuries when used as a liner in football helmets. Now, MSU engineers and scientists have improved this technology to shield vital as well.

Falls, motor vehicle crashes and other kinds of collisions can cause blunt force and damage to bodily organs that can lead to life-threatening emergencies. These injuries are often the result of intense mechanical force or pressure that doesn’t penetrate the body like a cut, but causes serious damage to the body’s organs, including internal lacerations, ruptures, bleeding and organ failure.

Read more | >

Early diagnosis is crucial in disease prevention and treatment. Many diseases can be identified not just through physical signs and symptoms but also through changes at the cellular and molecular levels.

When it comes to a majority of chronic conditions, early detection, particularly at the cellular level, gives patients a better chance for successful treatment. Detection of early changes at the cellular level can also dramatically improve cancer outcomes.

It’s against this backdrop that a University of Rhode Island professor and a former Ph.D. graduate student looked at understanding the smallest changes between two similar cells.

Read more | >

Empa researchers are working on producing artificial muscles that can keep up with the real thing. They have now developed a method of producing the soft and elastic yet powerful structures using 3D printing.

One day, these could be used in medicine or robotics—and anywhere else where things need to move at the touch of a button. The work is published in the journal Advanced Materials Technologies.

Artificial muscles don’t just get robots moving: One day, they could support people at work or when walking, or replace injured muscle tissue. However, developing artificial muscles that can compare to the real thing is a major technical challenge.

Read more | >

For decades, scientists have focused on amyloid plaques—abnormal clumps of misfolded proteins that accumulate between neurons—as a therapeutic target for Alzheimer’s disease. But anti-amyloid therapies haven’t made strong headway in treating the devastating condition.

Now, researchers at Yale School of Medicine (YSM) are zeroing in on a byproduct of these plaques, called axonal spheroids, and exploring how to reverse their growth. They published their findings March 10 in Nature Aging.

Axonal spheroids are bubble-like structures on axons—the part of the neuron that sends messages through electrical impulses—that form due to swelling induced by amyloid plaques. Previous research at YSM has shown that as these spheroids grow, they block electricity conduction in the axons, which can hinder the ability to communicate with other neurons.

Read more | >

Epstein-Barr virus (EBV) is a common virus that causes mononucleosis, or mono for short, and is associated with some types of cancer and autoimmune diseases. Despite EBV’s known effects and potential to cause disease, there are few therapeutic options and no licensed vaccines targeting the virus. Looking for ways to counter EBV, NIAID researchers are examining how the virus recognizes and interacts with cells at the molecular level. New research published in Immunity reveals the high-resolution crystal structure of a protein on the surface of EBV in complex with the receptor it binds to on the surface of human immune cells, called B cells. The researchers also discovered antibodies that potently neutralize EBV and found that they recognize the viral surface protein using interactions similar to those between EBV and its receptor on host cells. This research identifies a vulnerable site on EBV that could lead to the design of much-needed interventions against the virus.

EBV, also known as human herpesvirus 4, is one of the most common human viruses—nine out of ten people have or will have EBV in their lifetime. After being infected with EBV, many people experience no symptoms, but some experience symptoms of mononucleosis, such as fever, sore throat and fatigue. These symptoms are often mild but can be more severe in teens or adults. After the early stages of infection, the virus hides in the body and can emerge later in life or when the immune system is weakened. Recent studies have also found that EBV is linked to several types of cancer, autoimmune diseases including lupus, and other disorders.

A key step in EBV infection is for the virus to enter a cell in the body, which begins with the virus binding to a protein on the cell’s surface. The researchers, led by Dr. Masaru Kanekiyo, chief of the Molecular Immunoengineering Section at NIAID’s Vaccine Research Center, examined the atomic-level structure of an EBV surface protein called gp350 when bound to a protein on the surface of B cells called complement receptor type 2 (CR2). Usually, CR2 binds to a protein fragment, or ligand, called complement component C3d as a part of the immune response following a viral infection. The researchers found that the EBV protein precisely bound to the cell surface protein CR2 at the region where its natural ligand C3d binds, revealing that there is structural similarity between EBV and C3d in recognizing CR2 and how the virus exploits this interaction to enter and infect a cell.

Read more | >

Getting seven experiments on the International Space Station requires a really good idea. Like a brand new way to attack tumors—one that you can only make in space.

Space has unique advantages for making medicines. Its very makes it possible to grow molecules in shapes and uniformity that are difficult to create on Earth. If they can be reliably and affordably produced, such molecules could have all kinds of novel uses in industry and medicine.

University of Connecticut engineer Yupeng Chen has been growing one such unusually rod-shaped nanoparticle, called a Janus base nanotube, on the International Space Station (ISS).

Read more | >

Summary: New research highlights a critical link between antibodies produced against Epstein-Barr virus (EBV) and the development of multiple sclerosis (MS). Scientists discovered that these viral antibodies mistakenly target a protein called GlialCAM in the brain, triggering autoimmune responses associated with MS.

The study also revealed how combinations of genetic risk factors and elevated viral antibodies further increase the risk of developing MS. These insights may pave the way for improved diagnostics and targeted therapies, enhancing our understanding of the genetic and immunological interplay underlying this debilitating disease.

Read more | >